ArticleJournal of ophthalmology and advance research2026
Impact of Glucagon-Like Peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP) Receptor Agonists on Intraocular Pressure in Glaucoma: A Case Series.
Article in Journal of ophthalmology and advance research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Purpose: Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) are antidiabetic and weight management medications that bind to GLP-1 receptors throughout the body. Growing interest in this class has led to several retrospective cohort studies reporting a decreased occurrence of glaucoma in diabetic and non-diabetic patients with the use of GLP-1RAs, suggestive of anti-inflammatory and neuroprotective effects. Here we report five real world cases evaluating the impact of GLP-1RA and dual GLP-1/Gastric Inhibitory Polypeptide (GIP) receptor agonist use on Intraocular Pressure (IOP) measurements and subsequent disease management in glaucoma patients. Observations: Case 1 (severe pigment dispersion glaucoma OU) was started on semaglutide on two separate occasions and exhibited clinically significant declines in home IOP tonometry readings after each initiation (OD max: 20 to 18, 16 to 14; OS: 22 to 15, then 20 to 17). Case 2 (severe primary open angle glaucoma OU) was a candidate for filtration device surgery when he began taking tirzepatide, after which a decrease in home IOP tonometry readings was observed (OD: 11 to 8; OS: 21 to 14), resulting in surgery postponement. Case 3 (secondary glaucoma OD following trauma) began taking tirzepatide shortly following glaucoma drainage device implantation and experienced unexplained hypotony (IOP: 25 to 4). Case 4 (severe POAG OU) was taking semaglutide with stable IOPs until pancreatitis prompted cessation of semaglutide, whereupon an increase in IOP was subsequently observed (OD: 23 to 30; OS: 16 to 18). Case 5 (undiagnosed) is a patient naïve to IOP-lowering therapy and initiation of tirzepatide correlated with an abrupt reduction in IOP observed in clinic (OU: 24 to 10). Conclusion and Importance: These cases demonstrate a potential association between GLP-1/GIP receptor agonist use and IOP lowering in patients with glaucoma and help substantiate existing literature with real world cases, thereby highlighting the need for further prospective research on this emerging topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.